Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
about
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.Current Development Status of MEK Inhibitors.
P2860
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer.
@ast
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer.
@en
type
label
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer.
@ast
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer.
@en
prefLabel
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer.
@ast
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer.
@en
P2093
P2860
P50
P1433
P1476
Phase I/II Study of Refametini ...... in Advanced Pancreatic cancer
@en
P2093
Alberto Zaniboni
Anke Schulz
Barrett H Childs
Bohuslav Melichar
Colin Weekes
David Van Brummelen
Hanno Riess
Henrik Seidel
Jacek Jassem
Jean-Luc Van Laethem
P2860
P2888
P304
P356
10.1007/S11523-016-0469-Y
P577
2017-02-01T00:00:00Z
P6179
1046498925